NewcelX (NASDAQ: NCEL) sharpens Type 1 Diabetes cell therapy focus in new deck

Rhea-AI Filing Summary

NewcelX Ltd. furnished a 6-K announcing an updated corporate presentation and investor deck ahead of key spring 2026 investor and partnering conferences, including BIO-Europe Spring in Lisbon. The materials emphasize NewcelX’s primary focus on cell-based therapies for Type 1 Diabetes and its broader platform in metabolic and neurodegenerative diseases.

The updated presentation highlights recent scientific progress, clinical development priorities, and the company’s approach to restoring endogenous insulin production using regenerative medicine. It also introduces several new, internationally recognized members of the Scientific Advisory Board and leadership team, which NewcelX states will strengthen expertise across cell therapy development, translational medicine, clinical strategy, and commercialization.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of January 2026

Commission File Number: 001-39957

NEWCELX LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

CONTENTS

Press Release

On January 29, 2026, NewcelX Ltd., a corporation incorporated under the laws of Switzerland (the “Company”), issued a press release titled: “NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences” A copy of this press release is furnished herewith as Exhibit 99.1.

Investor Presentation

On January 29, 2026, the Company made available an investor presentation on its website. A copy of the investor presentation is furnished herewith as Exhibit 99.2.

EXHIBIT INDEX

Exhibit  Number		Description of Document
99.1		Press release titled: “NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences”
99.2		Investor Presentation

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NewcelX Ltd.
Date: January 29, 2026	By:	/s/ Ronen Twito
		Name:	Ronen Twito
		Title:	Chief Executive Officer

2

Exhibit 99.1

NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences

Reinforces strategic focus on Type 1 Diabetes cell therapy and highlights expansion of Scientific Advisory Board and leadership team

Zurich, Switzerland – January 29, 2026 — NewcelX Ltd. (NASDAQ: NCEL) (“NewcelX” or the “Company”), a clinical-stage cell therapy company advancing transformative treatments for chronic metabolic and neurodegenerative diseases, today announced the release of an updated corporate presentation in advance of its participation in several major spring 2026 investor and partnering conferences, including BIO-Europe Spring in Lisbon.

The updated corporate deck reflects NewcelX’s sharpened strategic focus on its lead cell therapy programs for Type 1 Diabetes, highlighting recent scientific progress, clinical development priorities, and the Company’s differentiated approach to restoring endogenous insulin production through regenerative medicine.

In addition, the presentation introduces several highly experienced and internationally recognized additions to NewcelX’s Scientific Advisory Board and leadership team. These appointments significantly strengthen the Company’s expertise across cell therapy development, translational medicine, clinical strategy, and commercialization, and further position NewcelX to execute on its near- and mid-term value creation milestones.

“Our updated corporate presentation clearly articulates NewcelX’s mission to deliver disease-modifying cell therapies, with Type 1 Diabetes now firmly established as our primary clinical focus,” said Ronen Twito, Executive Chairman & CEO of NewcelX. “Equally important, we are proud to welcome outstanding new scientific and operational leaders whose depth of experience materially enhances our ability to advance our pipeline and engage strategically with partners and investors. As we head into an active spring conference season, we look forward to sharing our progress and vision with the global biotech community.”

Management will be available for one-on-one meetings during upcoming spring conferences, including BIO-Europe Spring 2026 in Lisbon, where the Company plans to engage with potential partners, investors, and collaborators.

The updated presentation is available on the Company’s website at: Corporate Presentation

 

About NewcelX Ltd.

NewcelX Ltd. (Nasdaq: NCEL) is a clinical-stage biotechnology company focused primarily on developing cell-based therapies for Type 1 Diabetes, supported by a broader platform spanning neurodegenerative and metabolic diseases. The Company’s proprietary stem-cell technologies enable the scalable production of functional human cells for “off-the-shelf” therapeutic use, complemented by strategic collaborations and targeted in-house innovation. NewcelX is headquartered in Zurich, Switzerland, with research and development operations in Ness Ziona, Israel.

Social Media: LinkedIn, Facebook, X, Instagram

Website: www.newcelx.com

Investor & Media Contacts

Sarah Bazak, Investors relations

InvestorRelations@newcelx.com

Forward-Looking Statements

This press release contains expressed or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. For example, NewcelX is using forward-looking statements when it discusses advancing its pipeline and engaging strategically with partners and investors. These forward-looking statements and their implications are based on the current expectations of the management of NewcelX and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; potential delays or obstacles in launching or completing clinical trials; products that may not be approved by regulatory agencies; technologies that may not be validated or accepted by the scientific community; the inability to retain or attract key employees; unforeseen scientific difficulties with products in development; higher-than-expected product costs; results in the laboratory that do not translate to clinical success; insufficient patent protection; possible adverse safety outcomes; legislative changes; delays in developing or introducing new technologies, products, or applications; and competitive pressures that could reduce market share or pricing. Except as otherwise required by law, NewcelX does not undertake any obligation to publicly release revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (“SEC”) and available at www.sec.gov, as well as in subsequent filings made by NewcelX, including under the heading “Risk Factors” in its proxy statement/prospectus filed with the SEC on November 6, 2025.

FAQ

What did NewcelX (NCEL) disclose in its January 2026 Form 6-K?

NewcelX disclosed that it released an updated corporate presentation and investor deck ahead of major spring 2026 conferences. The materials emphasize its Type 1 Diabetes cell therapy focus, recent scientific progress, clinical priorities, and additions to its Scientific Advisory Board and leadership team.

What is NewcelX’s main therapeutic focus according to the new presentation?

NewcelX states that Type 1 Diabetes is now its primary clinical focus. The updated presentation centers on lead cell therapy programs aimed at restoring endogenous insulin production, supported by a broader platform in neurodegenerative and chronic metabolic diseases.

How does the updated NewcelX (NCEL) presentation describe its leadership and advisory changes?

The presentation introduces several highly experienced, internationally recognized additions to the Scientific Advisory Board and leadership team. NewcelX says these appointments strengthen capabilities in cell therapy development, translational medicine, clinical strategy, and commercialization to support near- and mid-term value creation milestones.

Which upcoming events will NewcelX participate in with its updated corporate presentation?

NewcelX plans to use the updated corporate presentation at several major spring 2026 investor and partnering conferences, including BIO-Europe Spring in Lisbon. Management will be available for one-on-one meetings with potential partners, investors, and collaborators during these events.

Where can investors find NewcelX’s updated corporate presentation and investor materials?

NewcelX indicates that the updated corporate presentation is available on its website. The 6-K furnishes the press release as Exhibit 99.1 and the investor presentation as Exhibit 99.2, providing investors with access to the latest strategic and clinical information.